- Recommendation ID
- IPG681/1
- Question
Evidence on the safety of pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis shows that this procedure can cause serious but well-recognised side effects. Evidence on its efficacy is inadequate in quality. Therefore, this procedure should only be used in the context of research. Find out what only in research means on the NICE website.
- Any explanatory notes
(if applicable) Further research should be in the form of randomised controlled trials comparing pressurised intraperitoneal aerosol chemotherapy with standard care. Studies should report details of patient selection including type of tumour, the chemotherapy drugs used, survival and quality-of-life outcomes.
Source guidance details
- Comes from guidance
- Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis
- Number
- IPG681
- Date issued
- October 2020
Other details
| Is this a recommendation for the use of a technology only in the context of research? | Yes |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 28/10/2020 |